At the pathway activation level, both Olamkicept and Tocilizumab showed a trend towards inhibition of STAT3 phosphorylation in BEAS-2B cells, however, it did not reach significance compared to the IL-6 + sIL-6Rα condition (Additional file 2 : Fig.
← all excerpts
An epithelial gene signature of trans-IL-6 signaling defines a subgroup of type 2-low asthma.
1
—
—